of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends.
All statements that address expectations or projections about the future, including without limitation, statements about product development, product launches, regulatory approvals, governmental and regulatory actions and proceedings, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA's "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following:
- the ability to continue as a going concern;
- the terms of our recently executed secured loan agreement with U.S. Healthcare I, L.L.C. and U.S. Healthcare II, L.L.C. (together, the "Lenders"), as more fully described in Item 1— "Business—(b) Significant Recent Developments—Financing" in the Company's Annual Report on Form 10-K for the year ended March 31, 2010 (the "Form 10-K"), could have an adverse effect on us if we are not able to refinance it or repay it at maturity on March 20, 2013, or earlier if we experience an event of default that is not waived by the Lenders or if a waiver expires and is not extended, and such terms contain numerous affirmati
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related medicine technology :1
|SOURCE K-V Pharmaceutical Company|
Copyright©2010 PR Newswire.
All rights reserved
. FDA Approves Viibryd to Treat Major Depressive Disorder2
. FDA Approves Head Lice Treatment for Children and Adults3
. FDA Approves Opioid Analgesic to Help Cancer Patients Manage Pain4
. VIDEO from Endo Pharmaceuticals Available on thenewsmarket.com: FDA Approves New Treatment for Low Testosterone5
. FDA Approves New Dosage Strength for INTELENCE®6
. U.S. FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels7
. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations8
. FDA Approves New Manufacturing Facility for Collagenase SANTYL® Ointment9
. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm10
. FDA Approves Xgeva to Help Prevent Cancer-Related Bone Injury11
. FDA Approves New Treatment Option for Late-Stage Breast Cancer